Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
12:02
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

ESMO 17th World Congress on Gastrointestinal Cancer 2015

 

1 - 4 July 2015 Barcelona
FAQs
   
Discussion forum - ESMO 17th World Congress on Gastrointestinal Cancer 2015
    Topic - Clinical Pancreatic Cancer

If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER
  
 Thread / Poster  Author  Replies  Last reply
Gemcitabine plus nab-Paclitaxel in metastatic or locally inoperable pancreatic cancer a single center experience  Ursula Vogl 1      7/1/2015 12:21:00 PM  
Decrement of Serum CA 19-9 Concentration after Initial Chemotherapy Predicts Favorable Outcome in Patients with Advanced Pancreatic Cancer  JIKON RYU 1      6/30/2015 1:14:00 AM  
Risk factors for febrile neutropenia in patients with unresectable pancreatic cancer receiving FOLFIRINOX as the first-line treatment.  Mitsuhito Sasaki 1      6/29/2015 8:53:00 PM  
Use of adjuvant chemotherapy after pancreatoduodenectomy for pancreatic cancer: a nationwide population-based study in the Netherlands  Maikel Bakens 1      6/29/2015 5:59:00 PM  
Socio-economic status influences likelihood of undergoing surgical treatment for pancreatic cancer in the Netherlands  Maikel Bakens 1      6/29/2015 5:56:00 PM  
Randomized phase III trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant therapy for patients with resected pancreatic cancer: APACT  Andrew Rhim 1      6/23/2015 3:40:00 PM  
nab-Paclitaxel (nab-P) plus gemcitabine (Gem) for patients with advanced pancreatic cancer who have cholestatic hyperbilirubinemia (CH) secondary to bile duct obstruction: a phase I safety and pharmacokinetics study  Andrew Rhim 1      6/23/2015 12:21:00 AM  
International phase II trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients with locally advanced pancreatic cancer (LAPC): LAPACT  Andrew Rhim 1      6/22/2015 11:53:00 PM  
The role of gastroenterologists in providing initial information on treatment options for patients with pancreatic cancer (PC) in the United States and Europe: a global quantitative survey  Andrew Rhim 1      6/22/2015 11:29:00 PM  
GEMCITABINE VERSUS FOLFIRINOX IN PATIENTS WITH ADVANCED PANCREATIC ADENOCARCINOMA HENT1 POSITIVE: BACK TO THE FUTURE.  Maria Alessandra Calegari 1      6/22/2015 10:08:00 PM  
NEOADJUVANT TREATMENT IN BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA: A SINGLE CENTER SERIES  Helena Verdaguer Mata 1      6/22/2015 9:32:00 PM  
Phase II trial of capecitabine nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma  Werner Scheithauer 1      6/22/2015 6:29:00 PM  
Phase II study of Gemcitabine and Curcumin (Meriva) as first line treatment for locally advanced or metastatic pancreatic cancer: preliminary data.  Caterina Soldą 1      6/21/2015 10:00:00 AM  
Efficacy of Various Endoscopic Transpapillary Sampling Methods for Malignant Biliary Lesions  Jong Jin Hyun 1      6/15/2015 2:29:00 PM  
       




Most viewed poster for this congress
Poster: 98
Visits: 485
Title: LOCAL ADVANCED GASTRIC CANCER: OPTIMIZATION OF MANAGEMENT
Authors: Oleg Kshivets ,
Centre: surgery department, Kaluga Cancer Center

Poster most viewed in this topic
Poster: 2
Visits: 159
Title: Socio-economic status influences likelihood of undergoing surgical treatment for pancreatic cancer in the Netherlands
Authors: Maikel Bakens ,
Centre: Catharina hospital Eindhoven


 




PosterSessionOnline
Logo Draft
 
Logo Cert